# Alnylam Pharmaceuticals, Inc.: Form 8-K, filed Nov 2, 2023

- Company: [Alnylam Pharmaceuticals, Inc.](/companies/alny.md) (CIK 1178670)
- Form: 8-K
- Filed: 2023-11-02
- Accepted by EDGAR: Nov 2, 2023, 08:10 ET
- Period: 2023-11-02
- Accession: 0001157523-23-001622
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1178670/000115752323001622/a53737945.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1178670/000115752323001622/

## Items reported

- Item 2.02: Results of operations
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1178670/000115752323001622/a53737945.htm

Filed Nov 2, 2023.
Source: SEC EDGAR, the filing index for accession 0001157523-23-001622. Last ingested by Listed: Nov 5, 2026, 13:51 ET. No prices; not investment advice.